IBRXImmunityBio, Inc.Running, no new patients
Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
Pancreatic Cancer
10Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due Oct 2025, none posted yet
Counts until it's fixed
Worry score10
Score over time
- Stage
- Phase 2
- Patients
- 328 (planned)
- Started
- Jul 21, 2020
- Main results expected
- Oct 13, 2025
- Fully finished
- May 31, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression Free Survival (PFS)
Measured over: 8 weeks
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2025-10-13, no fading
Raw record changes
- none yet
Trial ID NCT04390399 · record last updated 2026-11-02 · checked 2026-11-09 15:47 UTC